Hydroxylated Psilocybin Derivatives Reduce Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psilocybin compounds, despite their therapeutic potential, often cause adverse side effects such as panic attacks and psychotic states, necessitating the development of improved formulations with reduced toxicity and enhanced efficacy.
Innovation Solution
The development of hydroxylated psilocybin derivative compounds, which are synthesized through contacting a psilocybin precursor with a host cell containing psilocybin biosynthetic enzymes, offering variations in chemical structure that include hydroxy groups and phosphate groups, and are used in pharmaceutical or recreational drug formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin compounds are used for therapeutic purposes, then therapeutic potential is improved, but adverse side effects such as panic attacks and psychotic states increase
Solution Approach 1:
The patent modifies the chemical structure of psilocybin by introducing hydroxyl groups at specific positions (R2, R4, R5, R6, or R7) to create hydroxylated derivatives. This parameter change in molecular structure aims to alter the pharmacological properties to reduce adverse effects while maintaining therapeutic benefits. The specific hydroxylation positions are selected based on their impact on receptor binding and biochemical activity.
Solution Approach 2:
The patent creates composite chemical structures by combining the core psilocybin molecule with hydroxyl groups and other substituents (alkyl groups, phosphate groups, O-alkyl groups). These composite derivatives integrate multiple functional groups that work together to modulate the compound's interaction with 5-HT2A receptors and other targets, achieving a balance between efficacy and safety.
2Adaptability or versatility
If psilocybin compounds are used for recreational purposes, then psychoactive effects are achieved, but toxicity and adverse effects increase
Solution Approach 1:
The patent systematically varies chemical parameters by hydroxylating psilocybin at different positions and combining hydroxyl groups with other functional groups (alkyl, phosphate, O-alkyl). This creates a series of derivatives with modified psychoactive profiles and reduced toxicity, allowing for optimized recreational and therapeutic applications.
3Productivity
If hydroxylated psilocybin derivatives are synthesized through biosynthetic enzymes, then production efficiency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes host cells containing psilocybin biosynthetic enzyme complements to naturally produce hydroxylated psilocybin derivatives. The cells perform the synthesis themselves through their endogenous enzymatic pathways, converting psilocybin precursors into the desired hydroxylated forms without requiring external chemical intervention for the transformation steps.
Solution Approach 2:
The patent employs host cells as intermediary systems that facilitate the production of hydroxylated psilocybin derivatives. These cells serve as biological factories, taking psilocybin precursors and transforming them into the target compounds through their biosynthetic enzyme machinery, thereby simplifying the overall manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These hydroxylated derivatives aim to reduce adverse effects while maintaining therapeutic benefits, potentially providing improved safety and efficacy for psychiatric disorder treatment and modulation of 5-HT2A receptors.
Implementation Method 1
contacting a psilocybin precursor with a host cell comprising a psilocybin biosynthetic enzyme complement
Data Source
AI summary
Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.